Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to 1347.08%.

  • Taysha Gene Therapies' EBITDA Margin rose 5683000.0% to 1347.08% in Q2 2025 from the same period last year, while for Sep 2025 it was 1618.54%, marking a year-over-year decrease of 7332900.0%. This contributed to the annual value of 1097.55% for FY2024, which is 6287200.0% down from last year.
  • According to the latest figures from Q2 2025, Taysha Gene Therapies' EBITDA Margin is 1347.08%, which was up 5683000.0% from 930.54% recorded in Q1 2025.
  • Over the past 5 years, Taysha Gene Therapies' EBITDA Margin peaked at 7388.54% during Q1 2022, and registered a low of 1915.38% during Q2 2024.
  • Moreover, its 4-year median value for EBITDA Margin was 582.03% (2023), whereas its average is 636.8%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -77404100bps in 2023, then skyrocketed by 5683000bps in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' EBITDA Margin stood at 4135.33% in 2022, then crashed by -111bps to 450.78% in 2023, then crashed by -119bps to 985.76% in 2024, then tumbled by -37bps to 1347.08% in 2025.
  • Its EBITDA Margin stands at 1347.08% for Q2 2025, versus 930.54% for Q1 2025 and 985.76% for Q4 2024.